• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.05% Nasdaq Down0.18%

    SciClone Pharmaceuticals, Inc. (SCLN)

    7.14 Up 0.09(1.28%) 12:54PM EDT - Nasdaq Real Time Price
    ProfileGet Profile for:
    SciClone Pharmaceuticals, Inc.
    950 Tower Lane
    Suite 900
    Foster City, CA 94404
    United States - Map
    Phone: 650-358-3456
    Fax: 650-358-3469
    Website: http://www.sciclone.com

    Index Membership:N/A
    Industry:Drug Manufacturers - Other
    Full Time Employees:570

    Business Summary 

    SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, provides therapies for oncology, infectious diseases, and cardiovascular disorders in the People’s Republic of China, the United States, and Hong Kong. Its lead product is ZADAXIN, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as a vaccine adjuvant, and as a chemotherapy adjuvant for cancer patients with weakened immune systems. The company also focuses on development ZADAXIN for the treatment of sepsis. ZADAXIN has approval in approximately 30 countries, which include China, the Pacific Rim, Latin America, Eastern Europe, and the Middle East regions. The company markets and sells ZADAXIN through distribution arrangements, local importers, and distributors. In addition, it markets approximately seven partnered products in China, including Aggrastat, an interventional cardiology product. Further, the company holds license, promotion, distribution, or marketing agreements with various parties for products, including DC Bead, Holoxan, Mesna, Endoxan, Methotrexate, Estracyt, Farlutal, Neucardin, ProFlow, Angiomax, and Cleviprex. SciClone Pharmaceuticals, Inc. also has an agreement with MEDA Pharma GmbH & Co. KG for the development of Tramadol. The company was founded in 1989 and is headquartered in Foster City, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on SciClone Pharmaceuticals, Inc.

    Corporate Governance 
    SciClone Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Oct 1, 2015 is 6. The pillar scores are Audit: 10; Board: 3; Shareholder Rights: 6; Compensation: 5.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Friedhelm Blobel Ph.D., 66
    Chief Exec. Officer, Pres, Exec. Director and Member of Bus. Devel. Committee
    Mr. Wilson W. Cheung , 46
    Chief Financial Officer, Sr. VP of Fin. and Sec.
    Mr. Charles Meng , 52
    VP of Compliance and Gen. Counsel
    Mr. Hong Zhao , 52
    Chief Exec. Officer of China Operations
    Ms. Lan Xie , 42
    VP of Fin. and Chief Financial Officer of China Operations
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders